Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Tiragolumab in Post-PD-1 NSCLC and Solid Tumors
NCT03977467Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Aug 2019
- Primary completion
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, tiragolumab in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), triple-negative breast cancer (TNBC), Microsatellite instability-high solid tumors (MSI-H), sponsored by SCRI Development Innovations. Started Aug 2019; status: completed.
02
Drugs
atezolizumabtiragolumab
03
Conditions
non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)triple-negative breast cancer (TNBC)Microsatellite instability-high solid tumors (MSI-H)
Beyond the preview
Go deeper on NCT03977467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03977467.